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INTRODUCTION 
In the first of these two linked articles [l], the clinical 
importance of diarrheal diseases, the accompanying 
changes in gut flora and the mainstays of treatment 
were briefly described. It was demonstrated that, 
although the idea of using bacteria as biotherapeutic 
agents is theoretically interesting, the results of in vivo 
randomized, placebo-controlled, clinical trials have 
been disappointing, with the exception of Lactobacillus 
GG. In this second part, the use of yeasts will be 
discussed. The only yeast with which double-blind 
studes have been carried out is Saccharomyces boulardii. 
SACCHAROMYCES BOULARDll 
Saccharomyces boulardii is a non-pathogenic yeast which 
was isolated from lychees in Indochina, and which 
grows at the unusually high temperature of 37OC [2]. 
It is commercially available as a freeze-dried viable 
preparation, and is the only yeast with which double- 
blind studies have been carried out. Saccharornyces 
boulardii differs from baker's yeast Saccharomyces cerevisiae 
in a number of taxonomic, metabolic and molecular 
parameters [2]. 
PHARMACOKINETICS OF SACCHAROMYCES BOULARDII 
Saccharomyces boulardii survives gastric acid and bile and 
can be detected alive throughout the entire digestive 
Corresponding author and reprint requests: 
Yvan Vandenplas, Academic Children's Hospital, 
Free University of Brussels, Laarbeeklaan 101, 
1090 Brussels, Belgium 
Fax: +32 2 477 57 83 
E-mail: pedvsy@az.vub.ac.be 
Accepted 5 December 1998 
system if it is given daily in its freeze-dried form [3-6]. 
Two to five days after administration, the yeast becomes 
undetectable in the feces [3,7]. Saccharomyces boulardii is 
intrinsically resistant to antibacterial antibiotics. Simul- 
taneous administration in rats of Saccharomyces boulardii 
with clindamycin and ampicillin, which are active 
against anaerobic bacteria, increases the number of yeast 
cells recovered in the feces [8]. This was confirmed 
with ampicillin in human volunteers [5]. However, 
nystatin completely eliminates Saccharomyces boulardii 
from the gastrointestinal tract, although Saccharomyces 
boulardii can be administered 4-6 h after fluconazole 
without any effect on its viability in the intestine [9]. 
PHARMACODYNAMICS OF SACCHAROMYCES BOULARDll 
The pharmacodynamics of Sacrharomyces boulardii involve 
three different aspects: a direct antagonistic effect, an 
antisecretory effect, by acting specifically on the bind- 
ing of toxins to intestinal receptors, and a trophic effect, 
by stimulating enzymatic activities and intestinal defense 
mechanisms. Oral Saccharomyces boulardii induces several 
cellular and humoral immunologic changes in the peri- 
pheral blood of healthy volunteers [lo]. Saccharomyces 
boulardii activates C2, C3, C3a and C5a [l l] .  
Antagonistic effect 
In vitro, Saccharomyces boulardii reduces the growth 
of Candida albicans, Escherichia coli, Shigella species, 
Salmonella typhi and other microorganisms [12]. Saccharo- 
myces boulardii has been shown to inhibit the growth of 
Pseudomonas aeruginosa and Staphylococcus aureus in an 
enteral nutrient liquid into which these pathogens had 
been inoculated [13]. In vitro, Saccharomyces boulardii 
significantly reduces the number of red blood cells 
which adhere to Entamoeba histolytica, and the number 
of Entamoeba histolytica organisms in which red blood 
cells are found [14]. A significant reduction in the 
number and severity of signs of disease was observed in 
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rats inoculated with Entamoeba histolytica if Saccharomyces 
boulardii was administered [15]. Substances produced by 
Saccharomyces boulardii compete with the receptors of 
the target cells for Entamoeba histolytica [14]. In vivo, 
Saccharomyces boulardii reduces the Candida albicans 
population in mice 1 O-50-fold. This antagonistic effect 
is curative and preventive, and is reported for Candida 
krusei and Candida pseudotropicalis, but not for Candida 
tropicalis [15]. In immunodepressed mice (antibiotic 
decontamination and prednisolone injections), the 
adrmnistration of Saccharomyces boulardii significantly 
reduces the incidence of translocation of Candida albicans 
to the mesenteric lymph glands, liver and kidneys [16]. 
The addition of Saccharomyces boulardii to tetracycline 
treatment in severe salmonella enteritis reduces the 
mortality rate significantly [ 171. Similarly, Saccharomyces 
boulardii was shown to increase the survival ratio in 
Shigella pexneri infection and Staphylococcus aureus in- 
fection (significantly) and in Salmonella typhimurium 
infection (trend) [ 18,191. However, the protective effect 
of Saccharomyces boulardii in the reduction of the mor- 
tality and its effect at histologic level are not due to a 
reduction of the bacterial population in the intestine; 
the precise pathophysiologic mechanism is unknown 
POI. 
Antisecretory effect by acting specifically on the binding 
of bacterial toxins 
Two different mechanisms for activity against bacterial 
toxins have been discovered. Saccharomyces boulardii 
produces two proteins, one of 54kDa and another 
of 120 kDa. The 120-kDa protein has no proteolytic 
activity, and specifically competes with the hyper- 
secretion induced by Vibrio cholerae and enterotoxic 
Escherichia coli by reducing the formation of cyclic AMP 
in the intestinal cells [21]. Intestinal lesions caused by 
Vibrio cholerae remain absent or are less severe in rats 
given Saccharomyces boulardii [22]. In addition, Saccharo- 
myces boulardii was shown to reduce significantly sodium 
and water secretion in intestinal loops of rats which had 
been inoculated with V cholerae toxin [23]. A simdar 
reduction in hypersecretion was found in mice inocu- 
lated with enterotoxic and enteropathogenic Esckerickia 
coli if Saccharomyces boulardii was added [24-261. The 
second protein produced is a 54-kDa protease which 
acts on toxin A of Clostridium d@cile [26]. Saccharomyces 
boulardii significantly reduces the liquid secretion and 
permeability caused by toxin A in rat ileum [26,27]. 
In vitro, it has been demonstrated that the protease 
of 54 kDa digests both toxin A and the receptor on 
the enterocyte [28]. In vivo, Saccharomyces boulardii 
decreases the mortality rate, the quantity of toxin A 
and the intestinal lesions caused by Clostridium d@cile 
[29,30]. 
Trophic effect on the enterocyte with stimulation of 
enzymatic expression and intestinal defense mechanisms 
Polyamines, such as spermine and spermidine, cause 
s id icant  increases in length and weight of the intestine 
[31], accelerated maturation of the microviUous enzymes 
(lactase, sucrase, maltase and aminopeptidase) and in- 
creases in the immunoglobulin A secretion in villi and 
crypt cells in young test animals [32-361. Polyamines 
increase the number of glucose carriers in the mem- 
brane of the enterocyte, and are essential to achieve 
maximal glucose absorption in the enterocyte [37]. 
Saccharomyces boulardii contains polyamines (spermine, 
spermidine) and has similar trophic effect on the 
intestinal mucosa, with an increase in disaccharidase 
activity, as an equivalent amount of spermine and 
sperrnidine given to test animals [38]. Whether there is 
a stimulating effect on intestinal adaptation in short 
bowel syndrome is not clear, since contradictory results 
have been reported [39,40]. 
RANDOMIZED DOUBLE-BLIND STUDIES WITH 
SACCHAROMYCES BOULARDll (TABLE 1) 
Prevention of antibiotic-associated diarrhea 
The eflicacy of Saccharomyces boulardii in the prevention 
of antibiotic-associated diarrhea has been demonstrated 
in several clinical trials [41-43]. The preventive effect 
of a low dosage was demonstrated in patients treated 
with tetracycline or p-lactam antibiotics because of an 
upper respiratory tract infection [41]. Significant efficacy 
was demonstrated in the prevention of diarrhea in a 
hospital with a high incidence of antibiotic-associated 
darrhea and Clostridium d@cile [42,43]. Saccharomyces 
boulardii shortens the duration of antibiotic-associated 
diarrhea, with no relapse during a follow-up period of 
6 weeks. In the Saccharomyces boulardii group there was 
significantly less intestinal gas production and fever than 
in the control group. 
Prevention of diarrhea during enteral feeding 
Saccharomyces boulardii significantly reduced the number 
of days with diarrhea in patients hospitahzed in an 
intensive care unit and in patients with severe burns 
[44-46]. A higher caloric intake by enteral feeding was 
tolerated in patients treated with Saccharomyces boulardii, 
without symptoms of intolerance (diarrhea, vomiting, 
nausea). 
Prevention of travelers' diarrhea 
The effect of Saccharomyces boulardii in the prevention of 
travelers' diarrhea was demonstrated in 1231 people 
traveling to several destinations all over the world [47]. 
Participants were divided into three groups: a placebo 
group, a group receiving 250 mg/day Saccharomyces 
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Table 1 Randomized placebo-controlled double-blind studies with Saccharomyces boulardii 
Study Clinical outcome 
Reference population Indication (P value) 
43 193 Prevention of antibiotic-associated diarrhea <0.05 
42 180 Prevention of antibiotic-associated diarrhea <0.05 
41 388 Prevention of antibiotic-associated diarrhea <0.001 
44 40 Prevention of enteral feedmg-associated diarrhea <0.001 
46 128 Prevention of enteral feeding-associated diarrhea 0.002 
45 20 Prevention of enteral feeding-associated diarrhea <0.001 
in patients with severe burns 
47 1231 Prevention of travelers’ diarrhea <0.002 
7 124 Recurrence of Clostridium dflci le  colitis 0.05 
53 92 Treatment of acute diarrhea in adults <0.05 
54 130 Treatment of acute diarrhea in children <0.01 
57 40 Treatment of chronic marrhea in children <0.001 
58 35 Treatment of chronic diarrhea in AIDS patients <0.002 
(35/40: Ciardia lamblia) 
boulardii, and another group receiving 500 mg/day. 
The incidence of travelers’ diarrhea was 42.6%, 33.6%, 
and 31.8%, respectively (p<0.002). Regional differ- 
ences in the prevention of travelers’ diarrhea were 
observed. The preventive effect was highest in North 
and West Africa (58% and 59% reduction;p<O.Ol), and 
in various tropical islands (40% reduction; p <  0.05) 
[471. 
Treatment of (recurrent) chronic Clostridium difficile 
diarrhea 
Saccharomyces boulardii has a protective effect against 
toxin A, an enterotoxin, and toxin B, a cytotoxin, of 
Clostridium df ic i le  [48]. The addition of Saccharomyces 
boulardii for 1 month to standard antibiotic therapy 
(vancomycin and/or metronidazole) for Clostriditrm 
d f ic i le  infection significantly reduced the number of 
relapses [43]. The death rate in hamsters infected with 
Clostridium df ic i le  treated with clindamycin was signi- 
ficantly reduced if Saccharomyces boulardii was added to 
the treatment [49]. The effect was greatest in patients 
who relapsed at least once. In the end, the number of 
patients still positive for Clostridium df ic i le  or its toxin 
was significantly reduced in the Saccharomyces boulardii 
group (8.6% versus 26.8%) [43]. This randomized 
double-blind study confirmed the earlier results obtained 
with Saccharomyces boulardii in two open studies in 14 
patients with multiple Clostridium d@le relapses [50,5 11. 
The effect of Saccharomyces boulardii was investigated in 
an open study in 19 children, with a mean age of 8 
months, who had at least 2 weeks of chronic diarrhea 
without symptoms of colitis and in whom Clostridium 
df ic i le  with toxin B was detected as the single pathogen 
[52]. After 1 week of treatment, the symptoms (defe- 
cation fi-equency, duration and frequency of colic) had 
disappeared in 95% of the patients. In 85%, toxin B had 
disappeared after 2 weeks, and after 1 month Clostridium 
d@cile was no longer detectable in the feces in 73% of 
the patients [52]. 
Treatment of acute diarrhea in children and adults 
The efficacy of Saccharomyces boulardii was investigated 
in a randomized double-blind study in 92 adults with 
acute darrhea. After 48 h, a significant reduction of the 
diarrhea score (defecation frequency and consistency) 
was noticed [53]. The effect of Saccharornyces boulardii 
was demonstrated in a double-blind placebo-controlled 
study in 130 children, 3 months to 3 years old, with 
acute diarrhea [54]. After 48 and 96 h, significantly 
more children were clinically cured (less than four 
normal stools a day). The return to a normal stool 
consistency was significantly enhanced. Milk-based 
feeding could be continued in the Saccharomyces boulardii 
group without any side effects [54]. Two controlled 
studies evaluating the efficacy of Saccharomyces boulardii 
in the treatment of diarrhea in young children confirm 
these data: reduction in defecation frequency and 
improved consistency of feces, better weight gain, and 
rapid normalization of the gastrointestinal transit time 
[55,56]. 
Treatment of chronic diarrhea (giardiasis, shigellosis) 
The effect of Saccharomyces boulardii was investigated in 
40 children with chronic diarrhea caused by Giardia 
lamblia (35/40) or, Shigella species (4/40), or of 
unknown etiology (1/40) [57]. Patients with G. lamblia 
were treated for 5 days with tinidazole, and those with 
Shigella spp. were given trimethroprim-sulfamethoxa- 
zole; Saccharomyces boulardii or placebo was administered 
in addition to the antibiotic. After 1 month, the 
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number of stools per day was significantly (p=0.006) 
reduced in the Saccharomyces boulardii group. In addition, 
endoscopic intestinal lesions were reduced significantly 
(p=0.009). The overall histologic and clinical evalua- 
tion improved in 70% of the Saccharomyces boulardii 
treated group, compared to 10% in the placebo group 
(p=0.0007) [57]. 
Treatment of AIDS diarrhea 
In a randomized double-blind study in 35 AIDS 
patients with chronic diarrhea, 61% were found to 
be diarrhea-free after 1 week of treatment with 
Saccharomyces boulardii, compared to 12% in the placebo 
group (p<0.002) [58]. After one week, weight in the 
Saccharomyces boulardii group had increased by 2 kg, 
whereas the placebo group had lost a mean of 3.1 kg 
[58]. These results confirm an earlier open study in 17 
AIDS patients with chronic diarrhea for more than 1 
month. Saccharomyces boulardii normalized defecation 
frequency after 15 days ( h m  nine stools per day to 2.1 
per day), normahsed stool consistency and improved 
weight gain (mean of 4 kg in 2 weeks) [62]. 
Pilot studies and open studies 
Open studies with significant results favoring Saccharo- 
myces boulardii have been carried out in persistent 
travelers’ diarrhea, with ineffective prior treatment in 
two-thirds of the patients [60], in children with short 
bowel syndrome with bacterial overgrowth [59], and in 
patients with Crohn’s disease [61]. A positive effect was 
demonstrated in all. 
SIDE EFFECTS OF SACCHAROMYCES BOUURDll 
The commercial preparation of Saccharomyces boulardii 
contains minute, and thus clinically irrelevant, amounts 
of lactose, which wd,  in any case, be ‘digested’ by the 
duaccharidase-stimulating properties of Saccharomyces. 
The safety of Saccharomyces boulardii has been 
investigated in animal models and in randomized 
double-blind studies. In mice given 5% Saccharomyces 
boulardii for 70 days in their drinking water, no trans- 
location from the gastrointestinal tract was observed. 
Saccharomyces boulardii could not be detected in the 
organs (liver, kidneys, lungs and heart) or in the 
mesenteric lymph glands [2]. In an immunodepressed 
animal model (prednisolone and antibiotic decon- 
tamination), Saccharomyces boulardii could only be 
detected at very low concentrations in the mesenteric 
lymph glands; Saccharomyces boulardii could not be 
detected in the liver, spleen or kidneys [16]. Saccharo- 
myces boulardii was given to more than 40 AIDS 
patients, without any serious side effects being reported 
[58,62]. 
Over a period of 10 years, during which millions 
of Saccharomyces boulardii treatments have been prescribed, 
a few cases with Saccharomyces boulardii fungemia have 
been reported [63-701. All the patients thus far 
reported with Saccharomyces boulardii fungemia have 
had intravenous lines, with a majority of deep venous 
central catheters. In most patients a high dosage of 
Saccharomyces boulardii was given. All patients, except 
one, recovered after antimycotic treatment without any 
further problems. Careful deployment of Saccharomyces 
boulardii in patients with central venous lines is 
recommended. In one study, constipation and increased 
thirst was reported to occur [43]. Other side effects 
have not been reported 1711. 
CONCLUSIONS 
Biotherapeutic agents offer a large number of thera- 
peutic benefits in the prevention or treatment of several 
gastrointestinal disorders, including the management 
of acute and chronic infectious diarrhea, antibiotic- 
associated diarrhea and travelers’ diarrhea [71]. The 
critical evaluation of their efficacy is a challenge 
because many different microorganisms have been used 
in dfferent preparations and in different combinations. 
Although some in vitro studies provide very interesting 
results, the clinical utility of many bacterial biothera- 
peutic agents in vivo could frequently not be demon- 
strated. Some studies using Lactobacillus casei strain GG 
have produced promising data, although other studies 
provide contradictory results. Saccharomyces boulardii is 
a non-bacterial biotherapeutic agent, and is the only 
biotherapeutic agent with systematic convincing data 
from double-blind studies. Results show significant 
efficacy in the prevention and treatment of acute 
diarrhea. The WHO considers Saccharomyces boulardii to 
be a possible treatment for recurrent Clostridium d@le 
colitis [4]. 
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The author would like to take this opportunity to correct a clinical outcome in Table 1, Part I, CIin Microbiol Znzcct 
5: 302, for reference 55, study population 78, indication, acute diarrhea. We are happy to reproduce the complete 
table, incorporating the change, on the following page. 
Vandenplas :  Bacter ia  a n d  yeasts  in  t h e  t r e a t m e n t  of  i n f e c t i o u s  diarrhea-11. Yeasts 395 
Table 1 Randomized double-blind stumes with bacterial biotherapeutic agents 
Clinical 
Study Biotherapeutic outcome 
Reference population Indication agent p-value 
95 94 
27 48 
28 50 
38 38 
37 35 
29 319 
39 202 
40 71 
41 820 
42 71 
45 20 
47 287 
101 
186 
44 32 
49 16 
51 39 
53 17 
48 123 
96 39 
26 
39 181 
54 14 
55 45 
55 78 
56 114 
56 39 
57 97 
58 40 
59 55 
60 30 
61 143 
97 11 
Acute diarrhea in infants 
Diarrhea in ETEC-infected volunteers 
Travelers’ diarrhea 
Arnoxycillin-associated diarrhea 
Enteral feeding-associated diarrhea 
Travelers’ diarrhea 
Travelers’ diarrhea 
Acute diarrhea in children 
Travelers’ marrhea 
Acute diarrhea 
Enteral feeding in prematures 
Duration of diarrhea in children 
Duration of diarrhea if rotavirus positive 
Duration of diarrhea if rotavirus negative 
Non-bloody acute diarrhea 
Erythromycin-associated diarrhea 
Clostridium dficile colitis 
Atopic dermatitis with elimination diet 
Acute diarrhea 
Acute diarrhea in children 
Non-bloody diarrhea 
Travelers’ diarrhea 
Bacterial overgrowth 
Antibiotic-associated diarrhea 
Acute diarrhea 
Duration of Vibria cholerae diarrhea 
Duration of Escherichia coli diarrhea 
Duration of rotavirus diarrhea 
Duration of rotavirus diarrhea 
Prevention of diarrhea 
Prevention of diarrhea 
Prevention of diarrhea 
Chronic abdominal pain 
Streptococcus thermophilus 
Streptococcus factis 
Lactobacillus acidophilus 
Lactobacillus bulgaricus 
Lactobacillus bulgaricus 
Lactobacillus acidophilus 
Lactobacillus bulgaricus 
Lactobacillus acidophilus 
Lactobacillus bulgaricus 
Lactobacillus acidophilus 
Lactobacillus bulgaricus 
Lactobacillus acidophilus 
Lactobacillus acidophilus 
Lactobacillus acidophilus 
(heat killed) 
Lactobacillus acidophilus 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus GG 
Lactobacillus fermenturn 
Lactobacillus fermenturn 
Enterococcus faecium SF 68 
Enterococcusfaecium SF 68 
Enterococcusfaecium SF 68 
Enterococcusfaecium SF 68 
Lactobacillus reuteri 
Lactobacillus reuteri 
Streptococcus thermophilus 
Bijdobacterium bi jdum 
Bijidobacterium bi jdum 
Lactobacillus plantarum 299 V 
Lactobacillus plantarum 299 V 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
<0.001 
NS 
NS 
<0.05 
NS 
<0.01 
<0.05 
<0.001 
<0.05 
NS 
NS 
0.055 
NS 
NS 
NS 
<0.01 
NS 
NS 
NS 
NS 
0.035 
NS 
NS 
NS 
ETEC, enterotoxic Escherichia coli; NS, not statistically significant. 
